Posts

A Better Safety Net: How PSMA PET/MRI Is Catching Hidden High-Risk Disease in Men Choosing Active Surveillance or Focal Therapy

Image
A Pilot Study of 18F‐rhPSMA‐7.3‐PET/MRI to Reduce Mischaracterization of Active Surveillance and Focal Therapy Candidates With Occult Higher Risk Disease - Alam - The Prostate - Wiley Online Library Informed Prostate Cancer Support Group (IPCSG) Spring 2026  |  Volume XXIV  |  Imaging & Early-Stage Management Featured Research Review A landmark Northwestern University pilot trial — and a wave of supporting international research — shows that this advanced scan can find dangerous tumors standard MRI misses, changing one-in-three patients' treatment plans and dramatically boosting confidence for everyone involved. Compiled for the IPCSG Newsletter | March 2026 | Based on peer-reviewed research and FDA-approved clinical evidence Bottom Line Up Front (BLUF) A new pilot clinical trial from Northwestern University found that a next-generation scan — ¹⁸F-rhPSMA-7.3 PET/MRI (bran...
Post a Comment
Read more

When Cancer Moves Without Warning:

Image
The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy - Tsutsumi - The Prostate - Wiley Online Library Informed Prostate Cancer Support Group IPCSG Newsletter  ·  Patient Education Series Spring 2026 Vol. 28 / Treatment Monitoring Treatment Monitoring  ·  Advanced Prostate Cancer The Problem of PSA-Silent Progression A new study from Japan, along with a growing body of international research, reveals that a significant number of men on today's powerful hormone therapies can have cancer that spreads on imaging — even while their PSA levels look perfectly controlled. What does this mean for how you are being monitored? IPCSG Newsletter  ·  Research Summary for Patients and Families Bottom Line Up Front (BLUF) A critical gap in standard prostate cancer monitoring...
Post a Comment
Read more

Low Testosterone and the Risk of Prostate Cancer Progression

Image
Informed Prostate Cancer Support Group IPCSG Newsletter March 2026 | Patient Education Series Active Surveillance & Hormonal Biology Low Testosterone and the Risk of Prostate Cancer Progression: A Surprising Twist on an Old Story A landmark study from MD Anderson Cancer Center turns decades of conventional wisdom on its head — finding that men with low testosterone may face greater risk of their prostate cancer becoming more aggressive while under watchful waiting. Prepared for the IPCSG Member Community  |  March 2026  |  Based on peer-reviewed research through March 2026 Bottom Line Up Front (BLUF) A new study of 924 men on active surveillance found that those with low testosterone (≤300 ng/dL) had a 61% higher risk of their cancer progressing to an aggressive Grade Group 3 or higher. This challenges the century-old belief that high testosterone "feeds" prostate cancer. New scien...
Post a Comment
Read more

Epigenetic Inheritance of Disease Raises Concerns About Chemicals

Image
Epigenetic Inheritance of Disease Raises Concerns About Chemicals Newsletter · March 2026 Patient Education Series Environmental Health & Cancer Risk Toxic Inheritance: How a Single Chemical Exposure Can Shape Health Across 20 Generations Groundbreaking new research shows that pesticides and endocrine-disrupting chemicals can reprogram reproductive cells in ways that drive disease — including prostate disease — in descendants who were never directly exposed. The implications for understanding prostate cancer risk may be profound. |  March 2026  |  Based on peer-reviewed research and recent scientific releases Bottom Line Up Front (BLUF) A landmark study published in February 2026 in the Proceedings of the National Academy of Sciences found that a single prenatal exposure to the fungicide vinclozolin caused measurable disease — including prostate and kidney disease — across 20 subsequent generations of rats, with...
Post a Comment
Read more